DE602004024093D1 - 2,4-dioxo-3-chinazolinylarylsulfonylharnstoffe - Google Patents

2,4-dioxo-3-chinazolinylarylsulfonylharnstoffe

Info

Publication number
DE602004024093D1
DE602004024093D1 DE602004024093T DE602004024093T DE602004024093D1 DE 602004024093 D1 DE602004024093 D1 DE 602004024093D1 DE 602004024093 T DE602004024093 T DE 602004024093T DE 602004024093 T DE602004024093 T DE 602004024093T DE 602004024093 D1 DE602004024093 D1 DE 602004024093D1
Authority
DE
Germany
Prior art keywords
sub
sup
group
alkyl
member selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602004024093T
Other languages
English (en)
Inventor
Robert M Scarborough
Wolin Huang
Anjali Pandey
Shawn M Bauer
Xiaoming Zhang
Zhaozhong J Jia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Portola Pharmaceuticals LLC
Original Assignee
Portola Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Portola Pharmaceuticals LLC filed Critical Portola Pharmaceuticals LLC
Publication of DE602004024093D1 publication Critical patent/DE602004024093D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Non-Alcoholic Beverages (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE602004024093T 2003-10-03 2004-09-29 2,4-dioxo-3-chinazolinylarylsulfonylharnstoffe Active DE602004024093D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50856403P 2003-10-03 2003-10-03
PCT/US2004/032921 WO2005032488A2 (en) 2003-10-03 2004-09-29 2,4-dioxo-3-quinazolinylaryl sulfonylureas

Publications (1)

Publication Number Publication Date
DE602004024093D1 true DE602004024093D1 (de) 2009-12-24

Family

ID=34421757

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004024093T Active DE602004024093D1 (de) 2003-10-03 2004-09-29 2,4-dioxo-3-chinazolinylarylsulfonylharnstoffe

Country Status (16)

Country Link
US (1) US7109332B2 (de)
EP (1) EP1668002B1 (de)
JP (1) JP2007507551A (de)
KR (1) KR20060113700A (de)
CN (1) CN1863798B (de)
AT (1) ATE448222T1 (de)
AU (1) AU2004278030C1 (de)
CA (1) CA2540214A1 (de)
DE (1) DE602004024093D1 (de)
ES (1) ES2334795T3 (de)
HK (1) HK1093973A1 (de)
IL (1) IL174446A (de)
MX (1) MXPA06003618A (de)
PL (1) PL1668002T3 (de)
PT (1) PT1668002E (de)
WO (1) WO2005032488A2 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4743659B2 (ja) * 2003-12-22 2011-08-10 味の素株式会社 新規フェニルアラニン誘導体
AU2005292314B2 (en) * 2004-09-29 2011-11-03 Portola Pharmaceuticals, Inc. Substituted 2H-1,3-benzoxazin-4(3H)-ones
US8058284B2 (en) * 2005-11-03 2011-11-15 Portola Pharmaceuticals, Inc. [4-(6-halo-7-substituted-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylureas and forms and methods related thereto
US7834023B2 (en) * 2006-09-20 2010-11-16 Portola Pharmaceuticals, Inc. Substituted dihydroquinazolines as platelet ADP receptor inhibitors
CA2682207A1 (en) 2007-04-05 2008-10-16 Cv Therapeutics, Inc. Quinazolinone derivatives as aldh-2 inhibitors
US20100113391A1 (en) 2007-04-19 2010-05-06 Astellas Pharma Inc. Bicyclic heterocyclic compound
CA2686221A1 (en) * 2007-05-02 2008-11-13 Portola Pharmaceuticals, Inc. [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea salts, forms and methods related thereto
CN101654441B (zh) * 2008-08-19 2012-10-03 信谊药厂 抗凝化合物、组合物及其用途
MX2011007684A (es) 2009-01-19 2011-08-08 Abbott Lab Agentes inductores de apoptosis para el tratamiento del cancer y enfermedades inmunes y autoinmunes.
JP5613176B2 (ja) 2009-01-19 2014-10-22 アッヴィ・インコーポレイテッド 癌並びに免疫及び自己免疫疾患の治療用アポトーシス誘導剤
KR20140105445A (ko) 2011-10-31 2014-09-01 제논 파마슈티칼스 인크. 비아릴 에테르 술폰아미드 및 치료제로서의 그의 용도
ES2586213T3 (es) 2011-10-31 2016-10-13 Xenon Pharmaceuticals Inc. Compuestos de bencenosulfonamida y su uso como agentes terapéuticos
EA026393B1 (ru) 2012-05-22 2017-04-28 Дженентек, Инк. N-замещенные бензамиды и их применение в лечении боли
JP6309519B2 (ja) 2012-07-06 2018-04-11 ジェネンテック， インコーポレイテッド Ｎ置換ベンズアミド及びその使用方法
EP2968280A4 (de) 2013-03-14 2016-08-10 Genentech Inc Substituierte triazolopyridine und verfahren zur verwendung davon
US9493429B2 (en) 2013-03-15 2016-11-15 Genentech, Inc. Substituted benzoxazoles and methods of use thereof
MX2016006936A (es) 2013-11-27 2016-10-05 Genentech Inc Benzamidas sustituidas y metodos para usarlas.
CN106715418A (zh) 2014-07-07 2017-05-24 基因泰克公司 治疗化合物及其使用方法
MX2017010528A (es) 2015-02-16 2018-11-12 Univ Queensland Sulfonilureas y compuestos relacionados y uso de estos.
CN107835805A (zh) 2015-05-22 2018-03-23 基因泰克公司 被取代的苯甲酰胺和其使用方法
WO2017035271A1 (en) 2015-08-27 2017-03-02 Genentech, Inc. Therapeutic compounds and methods of use thereof
JP6987746B2 (ja) 2015-09-28 2022-01-05 ジェネンテック， インコーポレイテッド 治療用化合物及びその使用方法
EP3380466A1 (de) 2015-11-25 2018-10-03 Genentech, Inc. Substituierte benzamide als natriumkanalblocker
US10766858B2 (en) 2016-03-30 2020-09-08 Genentech, Inc. Substituted benzamides and methods of use thereof
PE20190980A1 (es) 2016-10-17 2019-07-09 Genentech Inc Compuestos terapeuticos y metodos para utilizarlos
US10793550B2 (en) 2017-03-24 2020-10-06 Genentech, Inc. 4-piperidin-n-(pyrimidin-4-yl)chroman-7-sulfonamide derivatives as sodium channel inhibitors
JP7235742B2 (ja) 2017-07-07 2023-03-08 インフレイゾーム リミテッド 新規なスルホンアミドカルボキサミド化合物
US11926600B2 (en) 2017-08-15 2024-03-12 Inflazome Limited Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors
JP2020531453A (ja) 2017-08-15 2020-11-05 インフレイゾーム リミテッド Ｎｌｒｐ３阻害剤としてのスルホニルウレアおよびスルホニルチオウレア
US11542255B2 (en) 2017-08-15 2023-01-03 Inflazome Limited Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors
SG11202003984UA (en) 2017-11-09 2020-05-28 Inflazome Ltd Novel sulfonamide carboxamide compounds
EP3759098A1 (de) 2018-02-26 2021-01-06 Genentech, Inc. Pyridinsulfonamidverbindungen und deren verwendung gegen schmerz und verwandte störungen
WO2019166619A1 (en) 2018-03-02 2019-09-06 Inflazome Limited Novel compounds
EP3774801A1 (de) 2018-03-30 2021-02-17 F. Hoffmann-La Roche AG Hydro-pyrido-verbindungen mit kondensierten ringen als natriumkanalinhibitoren
SG11202104243VA (en) 2018-12-06 2021-05-28 Daiichi Sankyo Co Ltd Cycloalkane-1,3-diamine derivative

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9702774D0 (sv) 1997-07-22 1997-07-22 Astra Pharma Prod Novel compounds
EP1047699A1 (de) 1998-01-15 2000-11-02 Cor Therapeutics, Inc. Platelet adp rezeptor inhibitoren
JP4574100B2 (ja) * 2000-02-04 2010-11-04 ポートラ ファーマシューティカルズ， インコーポレイテッド 血小板ａｄｐレセプターインヒビター
US6906063B2 (en) 2000-02-04 2005-06-14 Portola Pharmaceuticals, Inc. Platelet ADP receptor inhibitors

Also Published As

Publication number Publication date
CN1863798B (zh) 2011-08-31
MXPA06003618A (es) 2006-08-11
EP1668002B1 (de) 2009-11-11
CN1863798A (zh) 2006-11-15
EP1668002A2 (de) 2006-06-14
IL174446A0 (en) 2006-08-01
US7109332B2 (en) 2006-09-19
AU2004278030B2 (en) 2010-07-01
ES2334795T3 (es) 2010-03-16
KR20060113700A (ko) 2006-11-02
PT1668002E (pt) 2009-11-25
US20050107357A1 (en) 2005-05-19
AU2004278030C1 (en) 2010-12-02
HK1093973A1 (en) 2007-03-16
PL1668002T3 (pl) 2010-02-26
AU2004278030A1 (en) 2005-04-14
WO2005032488A2 (en) 2005-04-14
CA2540214A1 (en) 2005-04-14
IL174446A (en) 2012-02-29
JP2007507551A (ja) 2007-03-29
EP1668002A4 (de) 2006-12-20
WO2005032488A3 (en) 2005-05-12
ATE448222T1 (de) 2009-11-15

Similar Documents

Publication Publication Date Title
DE602004024093D1 (de) 2,4-dioxo-3-chinazolinylarylsulfonylharnstoffe
BG104248A (en) Benzamidoxim derivatives, intermediate products and methods for preparing and using them as fungicides
ATE449099T1 (de) Derivate des 2-trifluormethyl-6-aminopurins als phosphodiesterase 4 inhibitoren
MXPA04004457A (es) Novedosos derivados de 1,2,4-tiadiazolio como moduladores del receptor de melanocortina.
ATE366724T1 (de) Kondensierte heterocyclische derivate
HUP0402150A2 (hu) A CB1 jelzésű kannabinoid receptorra nézve agonista, parciális agonista vagy antagonista hatású 1H-imidazol-származékok, eljárás az előállításukra, azokat tartalmazó gyógyszerkészítmények és alkalmazásuk gyógyszerkészítmények előállítására
WO2007071632A3 (en) 2-pyridin-2-yl-quinazoline derivatives as potassium channel modulating agents for the treatment of respiratory diseases
EA200701779A1 (ru) Производные (1,5-дифенил-1н-пиразол-3-ил)оксадиазола, их получение и их применение в терапии
GR3034398T3 (en) 2-[1',2',4'-triazol-3'-yloxymethylene]-anilides and their use as pest-control agents
HRP20070286T3 (en) Substituted diketopiperazines and their use as oxytocyn antagonists
TW200609218A (en) Bicyclic compounds
HRP20050082A2 (en) 6-amino-1h-indazole and 4-aminobenzofuran compounds as phosphodiesterase 4 inhibitors
EA200401470A1 (ru) Производные пиперазинилацилпиперидина, их получение и их терапевтическое применение
MY146599A (en) New azetidine compounds
DE60336735D1 (de) Neue biologischaktive molekü le
HUP0003942A2 (hu) Helyettesített 3,3-diamino-2-propén-nitrilek, előállításuk és alkalmazásuk
NO20082226L (no) 6-heteroarylpyridoindolonderivater, deres fremstilling og terapeutisk anvendelse derav
IL160874A0 (en) 4-imidazolin-2-one derivatives
DE60213087D1 (de) Pyrimidin-derivate als selektive inhibitoren von cox-2
MXPA04003278A (es) Derivados de 5-metoxi-8-aril-?1,2,4?triazolo?1,5-a?piridina como antagonistas del receptor de adenosina.
PT1628968E (pt) Compostos de 4-imidazolin-2-ona
BR0307424A (pt) Compostos heterocìclicos com atividade inibidora de elastase e seus intermediários
EA200401099A1 (ru) Производные гетероциклического амида
EA200400470A1 (ru) Замещенные производные алкиламинопиридазинона, способ их получения и содержащие их фармацевтические композиции
ES2193047T3 (es) (3,4 dihydro-2h-benzo(1,4) oxazinilmetil)(3-(1h-indol-3-il)-alquil)-aminas.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition